Quantcast
Last updated on April 21, 2014 at 4:51 EDT

Latest Psi Stories

2011-04-11 06:00:00

PSI (Population Services International) Joins World's Top Social Marketers at World Conference on Achieving Positive Change through Strategic Communications, Marketing and Behavior Change DUBLIN, April 11, 2011 /PRNewswire-USNewswire/ -- Global health organization PSI will be featured prominently throughout the 2(nd) World Non-Profit & Social Marketing Conference, which opens today in Dublin, Ireland. The two-day conference features leading thinkers from across the world in the field...

2011-03-30 05:45:00

PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously. "We are encouraged by the early efficacy and safety data being generated with our...

2011-03-15 10:00:00

BURLINGAME, Calif., March 15, 2011 /PRNewswire/ -- PolyCore Software, Inc. (PSI), leader in multicore development software, today announces the next generation of Poly-Messenger®/MCAPI, furthering the adoption of the Multicore Association's (MCA) Multicore Communications API (MCAPI), by version 2.0 support and bringing to the industry, next-level solutions for multicore application design. MCAPI is defined by the MCAPI working group, chaired by PSI president and CEO,...

2011-02-24 09:06:00

Barbara Pierce Bush, Ambassador Frans Engering, Harvard Economist David Bloom, and Tuck Professor Punam Keller join board of leading global health organization WASHINGTON, Feb. 24, 2011 /PRNewswire-USNewswire/ -- PSI, one of the world's leading global health organizations known for its market-based solutions to health, today announced the appointment of four new members to its governing board: Barbara Pierce Bush, the President of Global Health Corps and daughter of U.S. President George...

2011-02-07 15:30:00

PRINCETON, N.J., Feb. 7, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended December 31, 2010. Financial Results Revenues were $0.2 million during the quarter ended December 31, 2010 compared to $0.3 million for the quarter ended December 31, 2009 and include...

2011-01-06 05:45:00

PRINCETON, N.J., Jan. 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study. Pipeline Update and 2011 Highlights PSI-7977 In August 2010, we began dosing of PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a Phase 2b study. This...

2010-12-07 14:00:00

LAS VEGAS, Dec. 7, 2010 /PRNewswire/ -- Intermittent renewables--wind and solar--are positioned by state Renewable Portfolio Standards (RPS) to become a "game-changer" in terms of grid operation and generation asset management. Depending on RPS, grid, and market specifics, some sections of the country could face electric system reliability issues within a year or two. This was one conclusion of technical experts participating in a special workshop, "Integrating Renewables Into the...

2010-11-30 05:45:00

PRINCETON, N.J., Nov. 30, 2010 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has begun in Part 2 of a Phase 1 study. This is the first clinical study combining a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for HCV, and is designed to evaluate once daily doses of PSI-7977 and PSI-938 in patients with HCV who have not been treated previously. "We are excited to be initiating this combination study with two proprietary nucleotide...

2010-11-23 15:56:00

PRINCETON, N.J., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2010. At fiscal year end Pharmasset held $127.1 million in cash and cash equivalents. Pipeline Update and 2010 highlights RG7128 Phase 2b PROPEL and JUMP-C trials...

2010-10-27 16:17:00

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, October 31, 2010 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD. To access a simultaneous webcast of this event via the internet, log on to the "Events &...